#Liechtenstein #Vaduz #Implantica #GERD #RefluxStop®

RefluxStop®: A Game Changer in GERD Treatment at DDW 2026

Implantica AG, a pioneering medtech company, recently showcased its groundbreaking RefluxStop® device at the Digestive Disease Week (DDW) 2026 held in Chicago. This innovative technology addresses the challenges faced by the approximately one billion individuals suffering from gastroesophageal reflux disease (GERD) worldwide. At this year's event, significant interest was generated surrounding the unique operational mechanism of RefluxStop® and the impressive clinical results it has achieved.

One of the highlights of the event was the presentation by Dr. med. Yves Borbély, an independent surgeon from the Inselspital Bern in Switzerland and a key figure in RefluxStop® surgeries. Dr. Borbély shared compelling data from his long-term study involving 82 patients over a period of up to 87 months, which underscored the device's exceptional safety profile and clinical efficacy. These results are consistent with the preliminary data traditionally associated with RefluxStop®, further reinforcing the device's reliability.

Every year, DDW gathers more than 13,000 medical professionals from over 100 countries, making it the largest international meeting focused on digestive health. It is collectively sponsored by prominent organizations such as the American Gastroenterological Association and the American Society for Gastrointestinal Endoscopy. The platform provides unparalleled opportunities for sharing the latest scientific advancements, and for Implantica, this year was particularly advantageous.

Noteworthy comments regarding the RefluxStop® device came from leading gastroenterologist Dr. Peter Kahrilas, who serves as a Professor Emeritus at Northwestern University. Dr. Kahrilas emphasized the urgent demand for surgical solutions that can address the needs of patients with GERD, stating that the introduction of RefluxStop® could represent a significant transformation in treatment protocols. He identified a current gap in existing surgical approaches, where many patients are not suitable candidates, highlighting the potential impact of RefluxStop® once approved by the FDA.

Another expert, Dr. John Lipham, a distinguished foregut surgeon from the University of Southern California, expressed enthusiasm over the long-term results presented at DDW. He noted that these promising outcomes indicate minimal side effects compared to traditional surgical options, thereby enhancing patient quality of life. Dr. Lipham looks forward to the positive changes RefluxStop® could bring to eligible patients upon potential FDA approval.

Implantica's CEO, Dr. Peter Forsell, also shared insightful commentary during the event. He expressed satisfaction with the enthusiastic response from U.S. surgeons and gastroenterologists and reiterated the urgent need for effective tools that can manage GERD without the debilitating side effects associated with past treatments. According to Forsell, nearly 23% of U.S. adults are affected by GERD, underscoring the necessity for accessible surgical solutions like RefluxStop® that retain an individual’s quality of life.

The RefluxStop® device distinguishes itself from traditional surgical methods for GERD treatment by addressing the root cause of acid reflux without encircling the esophagus. Unlike conventional approaches that often lead to significant complications, RefluxStop® supports the lower esophageal sphincter in its natural position, thereby reducing the risk of negative effects previously documented in standard anti-reflux surgeries. This innovative solution reconstructs key components of the anti-reflux barrier while allowing the body to self-regulate the reflux issue.

With 35 published studies, among many more underway, the clinical support for RefluxStop® continues to grow. Potent positive feedback from experts during DDW reinforces hope that FDA approval is on the horizon, setting the stage for a new era in GERD management. Implantica is poised to deliver this innovative solution to patients desperately seeking effective treatments for their condition, with the promise of improved outcomes and quality of life.

In summary, the enthusiastic reception of RefluxStop® at DDW 2026 marks a significant milestone in the future of GERD treatment. With ongoing clinical research and expert backing, the prospect of FDA approval for this revolutionary device could usher in comprehensive changes in how GERD is understood and addressed in clinical settings.